Skip to main content
OpenTrials
Completed

NCT Number: NCT01173042

Effects of Peanut Consumption on Postprandial Inflammation, Glucose and Triglycerides

This pilot study will investigate the effects of acute peanut consumption on markers of inflammation, triglycerides and glucose. The hypothesis is that a high glucose/SFA meal will increase postprandial production of the inflammatory marker, C-reactive protein (CRP), and that the addition of peanuts to the control meal will reduce the production of CRP, as well as triglycerides and glucose.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Penn State University

University Park, Pennsylvania, 16802, United States

About this study

Previous research has demonstrated that a single meal high in saturated fatty acids (SFA) and glucose can induce increases in IL-6, TNF-α and CRP in abdominally obese and diabetic subjects. As over two-thirds of the U.S. population is overweight or obese, it is important to identify foods that can attenuate postprandial increases in lipids, glucose and inflammation in this population. Therefore, the purpose of the pilot study is to determine whether a high SFA / high glucose control meal will induce an acute inflammatory response in overweight individuals, and whether the addition of peanuts to this meal will ameliorate this response. To ensure that these effects are due to peanuts, and not to the increase in total fat, we will compare this response to another test meal that includes an oil blend with a similar fatty acid composition to peanuts.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI >28
  • LDL_C below 130 mg/dl
  • TG below 350 mg/dl
  • Blood pressure within normal ranges (below 140/90 mmHg)

Exclusion criteria

  • Smoking
  • Allergies to peanuts or dairy products
  • Known intolerance for high fat meals
  • History of CVD, kidney disease, diabetes or inflammatory disease
  • Use of non-steroidal anti-inflammatories or immunosuppressants
  • Conditions requiring the use of steroids
  • Use of medication or supplements for elevated lipids, blood pressure or glucose

Treatment and study plan

Peanuts

Dietary Supplement

Shake containing 3.0oz of peanuts (including skin) + control (heavy whipping cream, glucose and chocolate syrup)

Glucose and whipping cream

Dietary Supplement

An oral liquid glucose (75g) and fat (high saturated fat from 60g heavy whipping cream) load. Chocolate syrup is added for flavor.

Oil Blend

Dietary Supplement

Shake containing an oil blend (sunflower, sesame, olive and palm oils) + control (heavy whipping cream, glucose and chocolate syrup). The amount of oil added to the control will provide an equivalent amount of fat to that provided in 3 oz (85g) of peanuts

Primary outcomes

  1. Serum C-reactive protein

    Time frame: 0min

  2. Serum C-reactive protein

    Time frame: 60 min

  3. Serum C-reactive protein

    Time frame: 120 min

  4. Serum C-reactive protein

    Time frame: 240 min

Secondary outcomes

  1. Serum Glucose

    Time frame: 0 min

  2. Serum Insulin

    Time frame: 0 min

  3. Serum Triglycerides

    Time frame: 0 min

  4. Serum Glucose

    Time frame: 60 min

  5. Serum Glucose

    Time frame: 120 min

  6. Serum Glucose

    Time frame: 240 min

  7. Serum Insulin

    Time frame: 60 min

  8. Serum Insulin

    Time frame: 120 min

  9. Serum Insulin

    Time frame: 240 min

  10. Serum Triglycerides

    Time frame: 60 min

  11. Serum Triglycerides

    Time frame: 120 min

  12. Serum Triglycerides

    Time frame: 240 min

Sponsors and collaborators

Lead sponsor

Penn State University

Other

Collaborators

  • The Peanut Institute

Registry information

Official study title

Pilot Study of the Effect of Peanut Consumption on Postprandial Inflammatory Status, Glucose and Triglycerides

Acronym: PKEPEANUT

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Jul 30, 2010
Registry last updated
Aug 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.